16 January 2017

Enthalpy revisited – and retired

The relative importance of enthalpy versus entropy for protein-ligand interactions has been a subject of considerable attention. In a 2009 post we suggested that it might be worthwhile to focus on fragments that bind predominantly enthalpically, and in 2011 we highlighted a paper suggesting that enthalpic binders may be more selective than entropic binders. But the universe has a way of confounding pet models – as we acknowledged in 2012 (twice). The best way forward is often with lots of data, which is exactly what we have in a new paper in Drug Disc. Today by György Keserű and collaborators at the Hungarian Academy of Sciences, Astex, and AstraZeneca.

The data in this case are sets of 284 protein-ligand interactions with thermodynamic binding data from the literature, 782 from Astex, and about 230 from AstraZeneca. Commendably, these data are provided in 103 pages of supporting information.

In order to analyze the data, the researchers developed a new metric, the Enthalpy-Entropy Index:

IE-E = (ΔH+TΔS)/ΔG

If IE-E = 0, it means that enthalpy and entropy both contribute equally to the free energy of binding; if IE-E > 0 it means that enthalpy dominates, and if IE-E > 1 it means that enthalpy needs to overcome an unfavorable entropy. Similarly, negative values mean that entropy dominates – completely so when IE-E < -1. (Note that, unlike enthalpy efficiency, this is a dimensionless ratio, which should please our friends over at Molecular Design.)

As it turns out, the vast majority of fragments bind to their targets with favorable enthalpy, and almost all of those that don’t are charged compounds in which desolvation of the charged bit could entail an enthalpic cost. The researchers also examined a set of 94 neutral fragment-sized and 44 larger molecules binding to 17 targets and found that, statistically speaking, enthalpy plays a more important role in the free energy of binding for fragments than for larger molecules. But things can change quickly: in one case, adding just two non-hydrogen atoms to a molecule improves the affinity by more than 4000-fold and changes the IE-E from -1.5 to +0.5.

The paper does an excellent job describing the challenges of collecting high-quality isothermal titration calorimetry (ITC) data. In a typical experiment, the heat measured with each injection is the same as “would fall on an A4 sheet of paper in 1 second when illuminated by a 40 Watt bulb placed nearly 5 kilometers away.” Errors can be caused by inaccurate concentrations, heat of dilution, and changes in buffer concentration or protonation state. An analysis of replicate measurements at Astex found that, while most of the replications were within 1 kcal/mol of each other, some were off by nearly 3 kcal/mol. However, these larger values were all associated with different forms of the protein, and so may not be considered true replicates, though they do indicate how changes in the protein far from the active site can have an effect on what is often considered (erroneously) a local interaction.

This also emphasizes the fact that, as the researchers note, “the measured binding enthalpy is a net value and the dissection of the individual contributions might be ambiguous.” Or, as Pete has previously stated, “the contribution of an individual protein-ligand contact is not strictly an experimental observable”.

From a molecular recognition standpoint I find all this quite interesting and even intuitive in a hand-wavy sort of way. As the researchers suggest, fragments, being small, have minimal surface area with which to make (often but not always entropically-driven) hydrophobic interactions. Instead, much of the binding energy comes from hydrogen-bond interactions, which are (again often but not always) predominantly enthalpic. Moreover, since the entropic cost of locking down any ligand onto a protein is on the order of 3-5 kcal/mol, fragments are already fighting against entropy, and this is exacerbated by low affinity.

But from a practical perspective, my earlier suggestion to focus on enthalpic fragments may have been simplistic: if you’ve found a fragment, its enthalpy of binding is almost certainly favorable, and even if it’s not, this could change with the slightest tweak. So unless we see something truly new, don’t expect many new posts on this topic.

11 January 2017

Cussed curcumin

Teddy’s retirement from the blog has cut down on the number of PAINS-shaming posts, and truth be told there are so many candidate papers that they could easily swamp fragments, which I suspect would drive away most of the readership. That said, I did want to highlight an exhaustive Perspective about a particularly diabolical natural product just published today in J. Med. Chem. by Mike Walters and collaborators at the University of Minnesota, Brigham and Women’s Hospital, and the University of Illinois (and also covered in a news story in Nature.)

We’ve previously discussed some of the types of artifacts that can plague small molecule screens: aggregation, covalent adducts, redox cycling, fluorescence, photoreactivity, and more. Curcumin is a jack of all trades in that it is capable of all of the above. It’s also unstable even at neutral pH, and can decompose into other reactive species. It is the quintessential chemical con artist: if you have an assay, curcumin will probably be active in it.

The new paper is a thorough investigation (18 pages, with 164 references) of the chemistry and biology of curcumin, covering in gruesome detail all the many ways it can deceive. After discussing the history and physicochemical properties (and liabilities), several literature case studies where curcumin is proposed as having biological activity are explored and thoroughly demolished; one of these has been retracted but continues to be cited uncritically years later.

One might expect that something which hits so many assays would be toxic. This turns out not be the case: curcumin is present at 1-6% in tasty turmeric and only seems to show any adverse events at very high doses – several grams per day. The reason, the researchers show, is that curcumin’s pharmacokinetics are lousy, with oral bioavailability of less than 1%. This is a very literal example of the cliché “garbage in, garbage out.”

Sadly, these properties have not dampened interest in testing curcumin in people. The researchers identify 135 registered clinical trials, only eight of which have reported study results, with 49 either recruiting or not yet recruiting. The few examples where results have been reported are not particularly encouraging.

Typing curcumin into PubMed pulls up close to 10,000 papers, with more than 150 published in J. Med. Chem. alone. Will this devastating exposé help? For honest and diligent researchers, it should serve as a flashing warning to be extremely careful with any data gathered using curcumin. Unfortunately, some in the scientific community may not care as long as they are able to pump out papers. Indeed, according to Wikipedia, at least one prominent curcumin researcher had to retract several papers because of questionable “data integrity”. And there may be still darker motives: type curcumin into Google and the top results are ads touting the stuff. There’s money to be made, and even more if you slap on some scientific lipstick.

And despite specific J. Med. Chem. author guidelines to be cautious about “interference compounds” and “provide firm experimental evidence in at least two different assays that reported compounds with potential PAINS liability are specifically active and their apparent activity is not an artifact”, the journal recently published a paper fully devoted to the synthesis and SIR of rhodamine derivatives, with no consideration of mechanism nor mention that they can be problematic. (Indeed, the researchers do not even bother to include detergent in their enzymatic assay!)

All of which is to say that it’s easy to publish crap. But hopefully now, more people will recognize it as such.

09 January 2017

Fragments in the clinic: verubecestat

Of all the fragment-derived drugs in the clinic, perhaps none is so closely watched as verubecestat (MK-8931), Merck’s BACE1 inhibitor in phase 3 clinical trials for Alzheimer’s disease (AD). With tens of millions of cases worldwide, few other diseases in the developed world are as simultaneously widespread, expensive, and terrifying. And despite billions of dollars thrown at the problem, failure rates are nearly 100%. A recent open-access paper by Jack Scott, Andrew Stamford, and collaborators at Merck and AMRI in J. Med. Chem. provides an excellent overview of this latest contender.

We first wrote about Merck’s BACE1 program almost exactly seven years ago, describing how an NMR screen had provided a weak hit that was optimized to nanomolar inhibitors of the enzyme. However, the molecules could fairly be called molecularly obese. This led the researchers to trim back portions of the molecule, losing affinity but gaining cell-based activity and permeability, ultimately resulting in compound 5 (below) – which is itself a fragment. The current paper describes the optimization of this molecule.

Growing compound 5 and expanding the heterocyclic ring led to compound 7, with low nanomolar biochemical and cell-based activity. The iminopyrimidinone core was becoming increasingly crowded from an intellectual-property standpoint, so the researchers replaced this with the iminothiadiazinane dioxide in compound 9, which modeling suggested should have a similar conformation – a result confirmed by crystallography. However, the alkyne moiety appeared to be metabolically unstable. More importantly, compound 9 was only 47-fold selective against the enzyme cathepsin D (CatD). An earlier Lilly BACE1 inhibitor with a similarly modest selectivity had failed due to toxicity possibly associated with CatD, and the researchers were keen to avoid a similar fate. This led them through additional rounds of optimization, ultimately resulting in verubecestat.

In addition to having low nanomolar biochemical and cell-based activity against BACE1, verubecestat is >45,000-fold selective against CatD, has good pharmacokinetics, is orally bioavailable, and is highly soluble (1.6 mM!) It does not inhibit CYP enzymes and has good brain penetration. Rule-checkers might be surprised at this later point given the high calculated polar surface area (115 Å2), a fact the researchers attribute to an intramolecular hydrogen bond between the amide and the pyridine nitrogen, effectively masking these moieties from the point of view of membranes.

A couple potential liabilities stood out. First, one metabolite is an aniline, and anilines can be mutagenic. Reassuringly, an Ames test on this particular aniline showed no mutagenicity. Also, verubecestat is a 2.2 µM hERG inhibitor, and inhibitors of this channel can cause cardiac arrhythmias. However, this concentration is significantly higher than the highest expected in humans, and studies in primates revealed no safety issues. All of which is a useful reminder that, in our business, rules are at most guidelines, and data is king.

The paper also includes some human data demonstrating that the compound is safe at doses up to 550 mg (!) and causes a dose-dependent reduction in β-amyloid levels. With the results of the first Phase 3 trial expected later this year, we could know soon whether this is a billion dollar molecule or yet another massively expensive failure. If the former, verubecestat could be one of those transformational advances in drug discovery that comes along once in a generation. But even if fails, this is the clearest test yet of the amyloid hypothesis. And fragments made it possible.

02 January 2017

Fragment events in 2017

What better way to start the year than with a list of upcoming conferences? Here's what we know about so far.

March 5-7: The UK may have voted to leave the EU, but that's not stopping the Royal Society of Chemistry from holding Fragments 2017 in Vienna, Austria. This is the sixth in an illustrious conference series that alternates years with the FBLD meetings. You can read impressions of Fragments 2013 and Fragments 2009. Registration is already open!

April 25-26: CHI’s Twelth Annual Fragment-Based Drug Discovery, the longest-running fragment event, will be held in San Diego at a brand new venue. You can read impressions of last year's meeting here; the 2015 meeting herehere, and here; the 2014 meeting here and here; the 2013 meeting here and here; the 2012 meeting here; the 2011 meeting here; and 2010 here. Also as part of this event, Ben Davis and I will be teaching a short course on FBDD over dinner on April 25. Early registration is open until January 27.

June 6-9: Although not exclusively fragment-focused, the fourth NovAliX Conference on Biophysics in Drug Discovery will have lots of relevant talks, and is a good excuse to get to Strasbourg, France. You can read Teddy's impressions of the 2013 event herehere, and here. Registration is open now.

July 23-28: Finally, Australia is coming into its own as a destination for fragment experts, many of whom will be participating in a symposium (on July 27) that is part of the Royal Australian Chemical Institute's Centenary Congress in Melbourne. The entire event should be huge - think ACS with wombats - so if you've been looking for yet another reason to travel Down Under, this is it. Early registration is open through April 23.

It looks like the year is largely front-loaded thus far - know of anything else? Add it to the comments or let us know!

26 December 2016

Review of 2016 reviews

This year is finally coming to an end, and as we've done for the past four years, Practical Fragments will highlight some of the reviews that we didn't cover previously.

In terms of what we did cover, there were several excellent events, including the eleventh annual CHI FBDD Conference in San Diego, an inaugural meeting in Houston, and of course the first-ever major fragment event in Boston, FBLD 2016.

The twentieth anniversary of SAR by NMR was also commemorated by the eighth book devoted to FBLD, as well as a massive two volume work on lead generation. We also covered a special issue of Molecules and reviews on clinical candidates and library design.

Another review on library design was published recently in Drug Disc. Today by Ian Gilbert, Paul Wyatt, and colleagues at the University of Dundee. The researchers have built a set of 356 diverse compounds consisting of “capped” scaffolds, such that any hits could be rapidly expanded. Undergraduates did much of the actual library assembly, learning skills such as parallel chemistry and how to work with polar compounds. There is lots of nice detail in this paper, including on library storage conditions.

Targets
Practical Fragments often highlights successful fragment to lead programs, and these were the focus of a Perspective in J. Med. Chem. by Christopher Johnson (Astex) and collaborators: all 27 cases published in 2015 in which the affinity of a fragment was improved at least 100-fold to a 2 µM or better lead. Many of these were covered in Practical Fragments, including BTK, DDR1/2, ERK2, MELK, Mtb TMK, PKCθ, RET, FactorXIa, MMP-13, BCATm, PDE10A, soluble epoxide hydrolase, tankyrase, ATAD2, MCL-1, RAD51, XIAP/cIAP, and mGluR5. The paper also draws general conclusions about target types, molecular weights, cLogP values, and LE.

Targeting tuberculosis (TB) is the subject of two reviews from University of Cambridge researchers, one in Drug Discov. Today by Vitor Mendes and Tom Blundell and one in Parasitology by Anthony Coyne, Chris Abell, and colleagues. Fragment-based approaches have been more or less successful against several TB proteins, including pantothenate synthetase, CYP121, BioA, EthR, and thymidylate kinase, while other targets – such as shikimate kinase and CYP144 – have proven more difficult.

July was bromodomain month at Practical Fragments, and this target class is the subject of a review in Drug Discov. Today: Technol. by Dimitrios Spiliotopoulos and Amedeo Caflisch at the University of Zurich. The focus is on computational fragment screening methods, with examples for BRD4 and CREBBP. And while we’re on the topic of computational methods, Olgun Guvench of SilcsBio has a brief review in Drug Discov. Today on computational functional group mapping.

Rounding out target-focused reviews, Paramjit Arora and colleagues at New York University focus on protein-protein interactions (PPIs) in a Trends Pharm. Sci. paper. This covers multiple approaches to finding PPI inhibitors, including fragment-based, and also touches on hotspots and structure-based design.

Biophysics
It is impossible to imagine FBLD without biophysics, and this is the topic of an authoritative review in Nat. Rev. Drug Disc. by Jean-Paul Renaud (NovAliX), Chun-wa Chung (GlaxoSmithKline), U. Helena Danielson (Uppsala University), Ursula Egner (Bayer), Michael Hennig (leadXpro), Rod Hubbard (University of York) and Herbert Nar (Boehringer Ingelheim). In addition to covering all the major techniques, the paper does a great job of delving into some of the more obscure and emerging methods, providing an excellent discussion of the throughput and requirements for each technique as well as the kinds of information obtained. Although the review is broader than FBLD, the application of biophysical techniques to fragments is a major theme. The researchers also remind us that, “contrary to the belief that all drug discovery challenges are best solved through the introduction of new technologies, substantial advances can also be driven by innovative application.”

Individual biophysical techniques also received plenty of attention over the year, including three on NMR. The first, by Alvar Gossert and Wolfgang Jahnke (Novartis) in Prog. Nucl. Magn. Reson. Spectrosc., is a 44-page practical guide to identifying and validating protein ligands. This contains a wealth of information on most of the NMR methods you will ever likely encounter; it includes a handy chart summarizing the molecular weight and concentration limits for each technique, suggested workflows, and thorough discussions of potential pitfalls. The review may appear daunting to the novitiate – it is replete with equations and pulse sequences – but the writing is clear. In the end, much comes down to the concept of the “validation cross”, a rubric for assessing the integrity of both ligand and protein, and evaluating binding effects on both ligand and protein.

Two additional reviews, both from William Pomerantz and colleauges at the University of Minnesota, focus specifically on protein-observed 19F NMR. The first, a Perspective in J. Med. Chem., is a good general introduction. Despite being the 13th most abundant element on our planet, only five natural products are confirmed to contain fluorine. Introducing this element into proteins – as has been done in more than 70 cases – can be a useful approach for discovering new ligands. And if you want to start doing this yourself, a paper in Nature Protocols provides practical details.

Turning to other biophysical techniques, surface plasmon resonance (SPR) continues to be very popular, and is reviewed by Alain Chavanieu and Partine Pugnière in Expert Opin. Drug Discov. The paper provides a good general overview on using SPR for FBLD, covering the theory, history, various screening strategies, comparison to other methods, recent applications to a variety of different targets, and a suggested workflow.

Calorimetry is less commonly used for fragment screening, even though it can provide thermodynamic data. Michael Recht and collaborators at the Palo Alto Research Center and Zenobia discuss both enthalpy arrays as well as more conventional isothermal titration calorimetry (ITC) in a Methods Enzymol. chapter.

Chemistry
But while biophysics is important, FBLD would be nowhere without chemistry. In MedChemComm, Stefan Kathman and Alexander Statsyuk (then Northwestern, now University of Houston) review one chemical approach, covalent tethering. This touches on the original reversible (thermodynamically-controlled) disulfide tethering approach developed back at Sunesis but is primarily focused on irreversible (kinetically-controlled) methods. The paper does an excellent job summarizing challenges, potential pitfalls, design rules, and recent successes. As of early this year the Statsyuk lab had sent their 100-member covalent fragment library to nine different research groups, three of which had already identified hits. The review ends with some provocative questions, and it will be fun for practitioners to answer them as covalent approaches garner increasing attention.

Another chemical technique we’ve touched on is substrate activity screening (SAS), and this is reviewed in ChemMedChem by Pieter Van der Veken and collaborators at the University of Antwerp. All published examples are summarized, including the modified approach developed by the Van der Veken lab; some unpublished data are also discussed. The paper also includes a good general section on the subtleties and complexities of transforming substrates into inhibitors.

Finally, if all this is a bit too much, a good general review on FBLD was published in Pharmacol. Ther. by Martin Scanlon and colleagues at Monash University. This concise but thorough paper covers theory, history, library design, hit finding and characterization, and select clinical success stories. The longest section is devoted to chemical strategies for elaborating fragments, and includes some of the less commonly used methods such as target-guided synthesis, Tethering, and off-rate screening.

And that’s it for this year. Thanks for reading, and especially for commenting. Take care, do important work, and may 2017 be better than we can reasonably hope.

19 December 2016

Fragments vs Lp-PLA2: A new hope

A few months ago we highlighted work out of Astex and GlaxoSmithKline describing the fragment-based discovery of inhibitors of lipoprotein-associated phospholipase A2 (Lp-PLA2), an inflammatory disease target. Although low nanomolar compounds were identified, they had high clearance in rats. In a new J. Med. Chem. paper the team – led by Alison Woolford of Astex and Vipul Patel of GlaxoSmithKline – describes a completely new series of molecules with better pharmacokinetic properties.

Recall that the researchers had previously solved the crystal structures of 50 fragments bound to the “canyon-like” active groove of Lp-PLA2. Hydantoin 3 was one of these, and although it had no detectable activity in a biochemical assay, it did make contacts with residues in the catalytic site of the enzyme. A virtual screen of 16,000 related compounds identified 33 potential hits, and crystallographic and biochemical screening of these led to compound 5, with low micromolar activity.

The researchers were able to trim back the cyclohexyl group and remove one of the carbonyls with only a modest loss in affinity. They could also take advantage of extensive structural information from other fragment hits. For example, adding a nitrile from another fragment produced compound 13, with improved affinity.

Next, the researchers turned to the left side of the molecule, adding substituents to make a stacking interaction with a tryptophan residue in the protein – an interaction seen previously with a uracil fragment. Simple aromatic rings worked, but aliphatic heterocycles such as amines and sulfones were even better, with compound (S)-23 being among the best.

Although compound (S)-23 has only high-nanomolar potency in a biochemical assay, it is equipotent with darapladib in a whole plasma assay – despite the fact that darapladib is a picomolar inhibitor in the biochemical assay. The researchers attribute this difference to the fact that darapladib, which reached phase 3 trials, is a poster child for molecular obesity, while (S)-23 comes in with a svelte molecular weight below 400, very low plasma protein binding, and a solubility of at least 3.5 mM. The molecule is also permeable, does not inhibit CYP450s, is selective against the closely related PLA2-VIIB, and has low clearance in dogs. The clearance is higher in rats, but a closely related compound is better and also has high oral bioavailability.

This paper provides another example of finding a fragment with no detectable activity and advancing it to an attractive series. It illustrates the power of crystallography to reveal useful fragments as well as the importance of crystallography during lead optimization. Darapladib failed in two massive phase 3 clinical trials for cardiovascular disease, which probably poisoned GlaxoSmithKline's appetite for Lp-PLA2. Still, if future biological discoveries suggest new indications for this target, molecules from this series may provide a path back into the clinic.

12 December 2016

Fragments vs COMT revisited

Catechol O-methyltransferase (COMT) metabolizes neurotransmitters such as dopamine and is a validated target for Parkinson’s disease. In theory other diseases could be treated with COMT inhibitors too, but most of these contain – like dopamine itself – catechol moieties, and thus have lousy pharmacokinetics and poor brain penetration. Catechols in general are best avoided, and in a recent paper in J. Med. Chem. María Sarmiento and colleagues at Roche have found an alternate scaffold.

COMT is a magnesium-dependent enzyme, and the catechol binds to the magnesium ion. The researchers decided to target the pocket that binds the cofactor, S-adenosyl-L-methionine (SAM). They screened 6000 rule-of-three compliant fragments at 200 µM using surface plasmon resonance (SPR). First they examined wild-type enzyme in the absence of magnesium and SAM, and they also counter-screened against six variants containing mutations in the SAM binding site to exclude fragments that bound elsewhere. Even after this specificity profiling 600 hits remained. Dose-response curves whittled the number down to 200, all of which were examined using ligand-detected (CPMG) NMR. Hits from CPMG NMR were further studied using protein-detected (1H/15N HSQC) NMR. Finally, all 600 of the hits from the initial SPR screen/counter-screen assays were tested in an enzymatic assay. Only four fragments made it through all of these filters, three of which were pyrazoles such as compound 1.


Two years ago Teddy highlighted a paper from Takeda also focused on COMT, and there too pyrazoles predominated – an observation that didn’t escape the Roche researchers. In fact, compound 1 in the current paper is almost identical to compound 5 in the Takeda paper. Substructure searching and screening led to compound 4, which is identical to compound 7 in the Takeda paper. Whether COMT is really this choosy when it comes to fragment hits, or whether this reflects similarities in fragment libraries remains an open question.

But happily there’s more. The researchers used an iterative structure-guided fragment-growing approach to improve affinity. This ultimately resulted in compound 24, which is competitive with SAM and has mid-nanomolar activity. The solubility could be improved, and no other biological data are presented, but at least this paper demonstrates that it is possible to find potent inhibitors of COMT that are not phenols or catechols. 

05 December 2016

Molecules special issue:
Developments in Fragment-Based Lead Discovery

Last December the first-ever Pacifichem symposium on FBLD was held in Honolulu. Two of the organizers, Martin Scanlon and Ray Norton, invited participants to submit manuscripts to a special issue of Molecules, which has now published.

The collection starts with a very brief Foreword by me describing the Symposium itself. The first actual paper, from Qingwen Zhang and collaborators at the Shanghai Institute of Pharmaceutical Industry, WuXi AppTec, and China Pharmaceutical University, focuses on kinase inhibitors. The researchers examine fragment-sized substructures of 15 approved drugs that inhibit kinases and use these to design a high-nanomolar inhibitor of the V600E mutant form of BRAF, which modeling suggests should bind to the protein in the “DFG-out” conformation.

Next comes a fragment-finding paper from Thomas Leeper and collaborators at the University of Akron and the University of North Carolina, Chapel Hill. The researchers were interested in finding inhibitors of the glutaredoxin protein (GRX) from the pathogen Brucella melitensis, which causes brucellosis. An STD NMR screen of 463 fragments (each at 0.5 mM in pools of 5-7) resulted in 84 hits, though 75 also hit human GRX. Subsequent experiments including chemical shift perturbation and modeling identified a mM binder with modest selectivity over the human enzyme. Next, the researchers introduced several covalent warheads (including a rather exotic ruthenium analog), one of which led to improved affinity, though the stoichiometry was not determined.

The remaining papers are all reviews, starting with one on native mass spectrometry (MS) by Liliana Pedro and Ronald Quinn at Griffith University. This provides a good historical, theoretical, and practical overview of the technique generally, as well as various applications for fragment-screening. It also covers most of the published examples and discusses both the strengths (such as speed and low protein consumption) as well as the weaknesses (false positives and false negatives) of native MS.

NMR is up next, with a paper by Pacifichem organizer Ke Ruan and colleagues at the University of Science and Technology of China, Hefei. This provides a concise but detailed description of library design, ligand- and protein-detected fragment screening, structural model generation, and hit to lead optimization.

Protein-directed dynamic combinatorial chemistry (DCC) is tackled by Renjie Huang and Ivanhoe Leung, both at the University of Auckland. In addition to summarizing the theory and various literature examples, the authors do an excellent job covering the pros and cons of different types of chemistries and analytical techniques.

Next comes a review by Begoña Heras and collaborators at La Trobe University and Monash University on the subject of bacterial Dsb proteins, which are essential for disulfide bond formation in virulence factors. The review covers the biology as well as several approaches to finding inhibitors, some of which we’ve previously covered (here and here). There is much more to do: as the researchers conclude, “the development of Dsb inhibitors is still in its infancy.”

Finally, Ray Norton and colleagues at Monash University discuss applications of 19F NMR for fragment-based lead discovery. In addition to covering fluorine-containing fragments, the researchers also discuss using fluorine-containing probe molecules and – even more unusual – fluorine-labeled proteins, in this case using 5-fluorotryptophan. The paper includes previously unpublished results on how these latter two approaches can be used to understand protein-ligand interactions.

One nice feature of this journal is that it is open-access, so if you are lucky enough to be back in Hawaii this December you can pull up the papers on your smartphone while lying on the beach.

28 November 2016

How do cryptic pockets form?

Earlier this year we highlighted crystallographic work out of Astex showing that secondary ligand binding sites on proteins are common; in addition to an active site, an enzyme may have several other pockets capable of binding small molecules. Many of these secondary sites are present even in the absence of a ligand. But there are also “cryptic” binding pockets that only appear when a ligand is bound. These are the subject of a new paper in J. Am. Chem. Soc. by Francesco Gervasio and collaborators at University College London and UCB Pharma.

Cryptic pockets are appealing in part because they can salvage an otherwise unligandable target: a featureless flat surface involved in a protein-protein interaction may crack open to reveal a crevasse capable of binding small molecules. Finding these pockets computationally, though, is difficult. In the current paper, the researchers performed molecular dynamics simulations on three different proteins with known cryptic pockets, and the pockets remained mostly closed over hundreds of nanoseconds. Increasing the temperature didn’t help, and even when the simulations were started with structures of the protein-small molecule complexes (with the small molecules removed), the pockets quickly slammed shut. Further calculations suggested that the open forms of the proteins are thermodynamically unstable.

The nice thing about computational approaches is that – unlike Scotty – you can change the laws of physics. In this case, the researchers changed the simulated water molecules to be more attractive to carbon and sulfur atoms in the proteins. (They call this SWISH, for Sampling Water Interfaces through Scaled Hamiltonians). This caused the known cryptic sites to open up during molecular dynamics simulations, even in the absence of ligand.

Next, the researchers added very small fragments (such as benzene), and found that these caused the cryptic pockets to open even further. The researchers speculate that this might reflect how cryptic pockets form in the real world: a ligand could worm its way into a transient pocket, stabilizing it and exposing more room for another ligand (or a different part of the first ligand) to bind.

Of course, just because something shows up in silico doesn’t make it real; how do you avoid false positives? Once the researchers found cryptic pockets using “enhanced” water, they reran simulations using standard parameters to see which pockets remained. The researchers found that subtracting the “density” of fragments bound in a conventional molecular dynamics simulation from the density of fragments in a SWISH simulation causes minor, irrelevant pockets to disappear for their three test proteins, leaving only the known cryptic pockets. Running this subtraction experiment on the protein ubiquitin caused a couple weak superficial pockets to disappear, consistent with the absence of cryptic pockets in this protein.

SWISH is an interesting approach, and I look forward to seeing how it compares with other programs, such as Fragment Hotspots and FTMap. It would also be fun to apply SWISH prospectively to therapeutically important but currently undruggable targets to see whether it is worth taking another look at some of them.

21 November 2016

New tools for NMR

As most of you know, Teddy has retired from active blogging, which is unfortunate not just for the loss of his wit but also for the loss of his expertise – particularly regarding NMR. But you blog with the army you have, not the army you want, so I'll take a stab at two recent papers on the subject.

The first, published in J. Med. Chem. by Chen Peng and colleagues at software maker Mestrelab in collaboration with Andreas Lingel and colleagues at Novartis, describes an automated processing program for just about any type of ligand-observed NMR data. After going into some detail on how “Mnova Screen” works, the program was benchmarked on three experimental data sets (on undisclosed proteins) which had previously been processed manually. The first was 19F data from a collection of 19 mixtures of up to 30 fluorinated compounds each – 551 altogether. Here the program performed quite well, identifying 56 of the 64 hits identified manually and misidentifying only 4 compounds as hits. Most of the false positives and false negatives were close to the predetermined cutoff threshold, which can be set as stringent or lax as desired.

T1ρ and STD NMR experiments on 55 individual protein-compound complexes were also examined, and the results were similarly positive. Of course, single compound experiments are easy to analyze, and the real test was with a set of 1240 compounds in 174 pools. Here the program was not quite as good, missing 16 of the 50 manually identified hits and coming up with 74 hits that had not been identified manually. Although most of these were false positives, closer inspection revealed that 10 of them are probably real. Moreover, some of the “false negatives” should perhaps not have been classified as hits in the first place. Clearly the program isn’t perfect, but it does seem to be a quick way to triage large amounts of data.

Of course, ligand-detected NMR provides at best only limited information on binding modes, which is where the second paper comes in, published in J. Biomol. NMR. by Mehdi Mobli (University of Queensland), Martin Scanlon (Monash University) and collaborators at Bruker and La Trobe University. The researchers were interested in finding inhibitors of the bacterial protein DsbA, and a previous screen had identified a weak fragment that initially proved recalcitrant to crystallography.

One of the best methods to determine the binding mode of a ligand is to look at intermolecular NOEs, NMR signals which only show up when two atoms are in close proximity to one another. In theory you can look at NOEs from ligands to the backbone amide protons in proteins, but this is technically challenging for aromatic ligands, of which there are many. Proteins have plenty of methyl groups – so many in fact that it can be difficult to correctly assign each methyl group to a specific residue, leading some researchers to only focus on isoleucine, leucine, and valine (ILV). However, by carefully studying more than 5000 high-quality protein ligand complexes, the researchers found that looking at all the methyl groups in a protein (ie, including those found in alanine, threonine, and methionine) greatly increases the number of protein-ligand complexes suitable for analysis.

The researchers were able to assign most of the methyl groups in DsbA using several approaches, and this allowed them to identify 11 NOEs between their ligand and ILV methyl groups. Modeling was unable to provide a unique binding mode, but by including 8 more NOEs to threonine and methionine methyl groups a single binding mode for the ligand was determined. Crystallography came through in the end too and confirmed the NMR-derived model.

Teddy would normally end his NMR posts by stating – often forcefully – whether he thought the tools under discussion were practical or not. NMR is one of the most popular methods out there, so new tools are clearly welcome. Since I'm no expert on the subject, I'll ask readers to weigh in – what do you think?

14 November 2016

CYP121 revisited: fragmentation approaches

Three years ago we highlighted work out of Chris Abell’s lab at the University of Cambridge targeting CYP121, an important enzyme for the pathogen Mycobacterium tuberculosis (Mtb). Two new papers from his group discuss progress on this target using conceptually similar approaches.

A previous fragment screen had identified some very weak fragments, and merging had led to low-micromolar compound 2 – the starting point for a (free access) J. Med. Chem. paper by researchers at Cambridge, the University of Manchester, the Francis Crick Institute, and São Paulo State University. The researchers used a “retrofragmentation” or deconstruction approach: systematically dissecting the molecule into component fragments (such as compounds 4 and 5) to see which bits were most important. Group efficiency analyses revealed that the two lower aromatic rings were important, while the upper one was much less so.
Crystallography revealed that compound 2 did not make direct interactions with the active-site heme molecule in CYP121, so the researchers sought to create some by growing out from compound 4. This led to a nice increase in affinity (compound 19a). Incorporating the other ring led to compound 25a, with sub-micromolar affinity as measured by isothermal titration calorimetry (ITC). Of course, heme is common to every CYP – including those found in humans – raising the question of selectivity. Happily, compound 25a turned out to be reasonably selective for CYP121 compared with a panel of Mtb and human enzymes.

There’s lots more in this (30 page!) paper, including extensive SAR supported by crystallography, ITC, native mass spectrometry, and an interesting spectroscopic binding assay. But unfortunately, the compounds are not active in a cellular assay, and the researchers are trying to figure out why.

The second (open access) paper also takes a deconstruction approach, this time starting from the substrate cYW. Fragmentation of this and related cyclic dipeptide substrates into amino acid derivatives and analogs led to the testing of 65 commercial compounds in a thermal shift assay, resulting in seven hits that increased the denaturation temperature by more than 1 °C. Compound 1a was the most stabilizing, and a spectroscopic assay suggested interaction with the heme group.


The spectroscopic assay also revealed a high micromolar affinity for the fragment. Attempts to improve this ultimately led to compound 31, with comparable affinity as cYW but with improved ligand efficiency. The thioester could be replaced with only a modest loss in potency, and interestingly the stereochemistry of these molecules did not seem to make a difference. Compound 31 was also reasonably selective for CYP121 in a panel of other CYPs.

Both papers cover lots of ground. Reading some publications you can be lulled into thinking that FBLD is an easy progression of increasingly potent compounds. These examples are useful reminders that many compounds turn out to be dead ends, and that even potent and selective molecules may not have the desired biological effects. Sometimes doing everything right can still leave you short of the goal – at least for a while.

07 November 2016

Disrupting constitutive protein-protein interfaces

Protein-protein disruptions are notoriously difficult because the interfaces between proteins tend to be large and flat, with few of the deep pockets where small molecules prefer to bind. That's not to say they're impossible: the second approved fragment-derived drug targets a protein-protein interaction. This interaction, as with most others studied (see here, here, and here, for example), is transient: two proteins come together to transmit a biological signal, then dissociate. But many proteins form constitutive dimers or oligomers, and these tend to be even more challenging to disrupt. This is the class of targets discussed in a paper just published in J. Am. Chem. Soc.

Wei-Guang Seetoh and Chris Abell (University of Cambridge) were interested in the protein kinase CK2, a potential anti-cancer target. The enzyme is a tetramer containing two identical catalytic subunits (CK2α) and two identical regulatory units (CK2β). Previous experiments had shown that introducing mutations into CK2β that disrupted dimer formation decreased enzymatic activity and increased protein degradation. Would it be possible to find small molecules that did this?

Chris Abell is a major proponent of the thermal shift assay, in which a protein is heated in the presence of a dye whose fluorescence changes when it binds to denatured protein. The way this assay is normally conducted, small molecules are added, and if they bind to the protein they stabilize it, thus increasing the melting temperature (see here for an interesting counterexample).For oligomeric proteins, one might expect that anything that disrupts the oligomers would destabilize the proteins, thus lowering the thermal stability, and indeed this turned out to be the case in a couple model systems. Thus, the researchers screened dimeric CK2β against 800 fragments, each at the (very high) concentration of 5 mM. No fragments significantly increased the melting temperature, but 60 decreased the stability by at least 1.5 °C.

Best practice for finding fragments includes using multiple orthogonal methods, so all 60 hits were tested (at 2 mM each) in three different ligand-detected NMR assays: STD, waterLOGSY, and CPMG. Impressively, 40 of these showed binding in all three assays. There was no correlation between the binding affinity and the magnitude of thermal denaturation, which is not surprising because the thermal shift incorporates not just the enthalpy change of ligand binding but also the enthalpy change of protein unfolding. Thus, as the researchers note, “the extent of thermal destabilization cannot be used as a measure of its binding affinity.”

Next, all 40 confirmed fragments were tested at 2 mM to see whether they caused CK2β dimer dissociation, as assessed by native state electrospray ionization mass spectrometry (ESI-MS). 18 fragments shifted the equilibrium to monomeric protein, though interestingly no protein-fragment complexes could be observed. These 18 fragments also decreased dimerization in an isothermal titration calorimetry (ITC) assay.

There is still a long way to go: all the fragments are very weak, and preliminary SAR studies were unable to find analogs with significantly improved activity. Indeed, it is unclear where the fragments bind, or whether the binding site(s) are even ligandable. Still, the combined use of biophysical techniques on a particularly gnarly target make this an interesting study on the frontiers of molecular recognition.

31 October 2016

Fragments vs renin: growing this time

Renin is a key player in the regulation of blood pressure, and thus an important therapeutic target for hypertension. Indeed, the approved drug aliskiren is a renin inhibitor. However, this drug has very low oral bioavailability as well as other problems – surely something better could be developed? This was the goal of a team of researchers at Takeda, described in two recent papers in Bioorg. Med. Chem.

One challenge with renin is that it is an aspartic protease with a large active site – similar to the difficult target BACE1. Like BACE1, fragment-based approaches proved to be useful. In the first paper, Michiko Tawada and colleagues conducted an enzymatic screen (at 100 µM) of their fragment library. Although this library contained many positively-charged fragments – which would be expected to interact with the negatively charged catalytic aspartic acid residues – none came up as hits. Neutral compound 1, however, was identified, and crystallography revealed that it binds in the hydrophobic S1, S3, and S3sp pockets. Novartis researchers published a similar experience several years ago.

Compound 1 was poorly soluble, lipophilic, cytotoxic, and offered suboptimal vectors for fragment growing, so the researchers sought an alternative by constructing and testing a library of analogs. Compound 4a had a similar affinity to the initial fragment, and crystallography revealed a similar binding mode. This was used as the core of a second library, leading to compound 6b, which also displayed a similar binding mode to the initial fragment. Although the affinity was similar (and indeed, the ligand efficiency was lower), the new fragment had better physicochemical and biological properties. It was also more synthetically tractable for subsequent optimization, which is the focus of the second paper.

As with the initial fragment, compound 6b did not make interactions with the catalytic aspartic acid residues, though they are nearby. By redesigning the compound and introducing a basic nitrogen in compound 7, Yasuhiro Imaeda and colleagues were able to engage these residues. Also, the crystal structure of compound 4 (top) revealed that a hydrophobic substituent would be tolerated, which led to compound 9, with nanomolar affinity. Further growing into a hydrophobic pocket led to compound 14, with high picomolar activity. This compound was active in human plasma, showed excellent selectivity against other aspartic proteases, and exhibited encouraging bioavailability and pharmacokinetic properties. The paper notes that this molecule has been optimized further.

For me, the most striking lesson from these two papers is how much effort it took to improve the potency of the initial fragment hit: lots of analogs were made without notable improvements, and it would have been easy to give up. But in the end, a combination of managed serendipity and careful structure-based design increased the affinity by 74,000-fold to a promising lead. Something to keep in mind the next time you find yourself lost in a forest dark, where all paths seem to lead to dead compounds.

24 October 2016

Fragments vs secreted phospholipase A2: AZD2716

Many success stories were presented at the recent FBLD 2016 meeting in Boston, some of which are appearing in the literature. A case in point is published in this month’s issue of ACS Med. Chem. Lett.

Fabrizio Giordanetto, Daniel Pettersen, and colleagues at AstraZeneca were interested in finding inhibitors of secreted phospholipase A2 (sPLA2) enzymes, which cleave glycerophospholipids and are implicated in the lipid accumulation and inflammation associated with atherosclerosis. Of the eleven different isoforms, sPLA2-IIa, sPLA2-V, and sPLA2-X are considered particularly good targets, and the researchers sought an inhibitor that would hit all three. Other companies had shown that a primary amide can form multiple hydrogen bonds at the catalytic site, so the AstraZeneca team reanalyzed previous internal screening data to look for fragment-like hits (defined as having 10-18 non-hydrogen atoms) containing a primary amide. They found many, including compound 1.

In addition to being a potent inhibitor of both sPLA2-IIa and sPLA2-X, compound 1 was quite active in human plasma, which is physiologically relevant. A crystal structure of  sPLA2-X revealed that the compound bound as expected, and modeling suggested that adding a carboxylic acid moiety could make additional interactions with the catalytic calcium ion. Several molecules were made, the most potent of which turned out to be compound 4, with a satisfying 2000-fold boost in activity against sPLA2-X. Shortening or lengthening the linker connecting the acid with the rest of the molecule reduced affinity, observations which could be rationalized by modeling.

Compound 4 was characterized in some detail, which revealed bioavailability in rats and dogs, good pharmacokinetics, and a fairly clean off-target profile. Unfortunately, it was reasonably active against OATP1B1, which recognizes carboxylic acids. Among other duties, OATP1B1 transports statins to the liver, and since many people with atherosclerosis are taking statins this activity would obviously be a problem. However, crystallography suggested that introducing substitutions very close to the carboxylic acid moiety would likely be tolerated by sPLA2 but not by OATP1B1. Indeed, simply adding a methyl group maintained or increased activity against the three relevant sPLA2 isoforms while completely abolishing OATP1B1 inhibition. Happily, AZD2716 had excellent pharmacokinetics and bioavailability in mice, rats, dogs, and cynomolgus monkeys.

This is a lovely example of what has been called fragment-assisted drug discovery. The researchers explicitly looked for a small, ligand-efficient starting point and relied heavily on structure-based design during optimization. The paper ends by noting that AZD2716 was selected as a clinical candidate, though it does not appear in the AstraZeneca pipeline or in clinicaltrials.gov; if this changes we’ll make a note on our running list.

At FBLD 2016 Jenny Sandmark presented this story, and she also described another compound derived from a different fragment. This turned out to be selective for sPLA2-X over sPLA2-IIa and sPLA2-V, and was therefore deprioritized. The experience working with this earlier series was, however, useful in guiding the discovery of AZD2716 – a reminder of the importance of having multiple good fragment starting points.

17 October 2016

FBLD 2016

Last week the sixth FBLD meeting was held in Cambridge, MA. Like its predecessors in 2014, 2012, 2010, 2009, and 2008, this meeting was an enormous success, mixing more than 230 scientists with excellent (and liberal) food and drink. With 33 talks, more than 30 posters, and several vendor booths and workshops I won’t be able to do more than capture a few highlights.

The most striking feature for me was the number of success stories. This began with Steve Fesik’s keynote lecture, in which he discussed the MCL-1 inhibitors he and his team at Vanderbilt have discovered. When we highlighted his work last year he had reported low nanomolar inhibitors, but these did not have cell-based activity. His group has now optimized the molecules to low picomolar biochemical potency, low nanomolar cellular activity, and good activity in mouse xenograft models. This has not been easy: more than 2210 compounds were made, guided by 60 X-ray structures and dozens of pharmacokinetic experiments. It seems to be paying off though, and the researchers are developing biomarkers with the goal of advancing a compound into clinical testing.

Two other notable success stories about clinical candidates must be mentioned, though I’ll wait until publications come out before going into detail. Kathy Lee described how she and her colleagues at Pfizer chose a fragment that was less potent and ligand-efficient than other hits due to its interesting binding mode and were able to advance it to PF-06650833, an IRAK4 inhibitor with potential for inflammatory diseases. And Wolfgang Jahnke discussed how he and his colleagues at Novartis were able to discover and advance ABL001, an allosteric inhibitor of BCR-ABL, despite having the project halted twice – a reminder that persistence is essential.

Several other success stories have been covered at least in part on Practical Fragments, including inhibitors against PDE10A (presented by Izzat Raheem of Merck), Dengue RNA-dependent RNA polymerase (presented by Fumiaki Yokokawa of Novartis), lipoprotein-associated phospholipase A2 (presented by Phil Day of Astex), and BACE1 (presented by Doug Whittington of Amgen).

Crystallography was another theme, and several of the success stories relied on crystallographic fragment screening. Frank von Delft of the Structural Genomics Consortium described developments that allow screening 1000 crystals per week at Diamond’s Xchem facility in the UK, which include acoustic dispensing of compounds into crystallization drops – while carefully avoiding hitting the crystals head-on.

Several computational talks reported results that run contrary to conventional wisdom. Vickie Tsui of Genentech discussed their CBP bromodomain program (which we recently discussed here). Several water molecules form a highly ordered network in the protein, and a WaterMap analysis suggested that these were high-energy and that displacing them would lead to an enhancement in activity. Unfortunately this turned out not to be the case, though the researchers were able to get to low nanomolar inhibitors by growing towards a different region of the protein.

Li Xing mined the Pfizer database of 4000 kinase-ligand structures to extract 595 unique hinge binders. Not surprisingly, some of these – such as adenine and 7-azaindole – bound to multiple kinases, but 427 were complexed to just a single kinase. Hinge binders typically form 1 to 3 hydrogen bonds to the protein, and while there didn’t seem to be a correlation between the number of hydrogen bonds and potency, more hydrogen bonds did correlate – perhaps counterintuitively – with lower selectivity. To the extent that hydrogen bonds are thought of as enthalpic interactions, this further muddies the argument that enthalpy and entropy can be useful in drug design.

On a more positive note, Sandor Vajda (Boston University) suggested that, according to analyses done in FTMap, perhaps 60-70% of protein-protein interactions may be druggable – as long as we accept that this may require building larger molecules than commonly accepted. And Chris Radoux (Cambridge Crystallographic Data Centre) discussed the computational tool for characterizing hotspots that we previously covered here; a web server for easy search should be available soon.

Library design was also a key topic. Richard Taylor of UCB described his analysis of all FDA-approved drugs, which revealed >350 ring systems. Interestingly though, 72% of drugs discovered since 1983 rely exclusively on ring systems used prior to that date. Clearly there is plenty of untapped chemical real estate.

But getting there won’t necessarily be easy. David Rees stated that 33 fragments recently added to the Astex library required 13 different reaction types. Importantly, many of the fragment to lead successes at Astex have required growing the fragment from the carbon skeleton rather than from more synthetically tractable heteroatoms. Knowing in advance how to do this with every new member of a fragment library should make life much easier in the long run, though it is a serious challenge for chemists.

There is far more to write about, including a great discussion led by Rod Hubbard on how FBLD is integrated effectively into organizations and how it enables difficult targets, but in the interest of space I’ll stop here. If you were at FBLD 2016 (or even if you weren’t) please share your thoughts!

10 October 2016

Tips for high-throughput crystallography

X-ray crystallography is tied for second place among methods used in fragment-based lead discovery, according to our most recent poll. This makes sense, since structures are usually essential for advancing fragments to leads. Faster fragment-finding methods are usually used to triage fragments down to a manageable number of hits to feed into crystallography, but the high incidence of false negatives means that promising fragments might be inadvertently discarded. If structures are key goals at the end of a fragment screening campaign, why not start directly with crystallography?

In fact, this is exactly what more and more groups seem to be doing. The problem, historically, has been throughput. Increasing automation has been solving some of the mechanical issues (such as mounting crystals and collecting data at a synchrotron), but what about the actual processing? A recent paper in Structure by Andreas Heine and collaborators at Philipps-University Marburg and Helmholtz-Zentrum Berlin für Materialien und Energie provides some useful advice.

The protein in question is endothiapepsin, a model aspartic protease that is easy to crystallize and diffracts to high resolution. Earlier this year, we discussed the researchers’ work soaking 360+ fragments against this protein, and a companion paper gives detailed information on how several dozen fragment hits bind. The Structure paper describes an automated refinement pipeline, and highlights some of its most important features.

Determining a crystal structure involves iterative cycles of modeling the protein backbone and side chains into regions of “electron density.” One risk is “model bias,” illustrated memorably in this brief video. This is especially important for small molecules: since they represent such a tiny fraction of the overall structure, it is especially easy to see what you want to see. To avoid this, people often look for regions of electron density – which in addition to a bound small molecule could represent co-solvents, buffer, or an amino acid side chain that has unexpectedly moved – before doing much refinement.

The problem is that the electron density might be very spotty and easy to overlook. This is especially true for fragments that bind weakly and which are small by definition. Some initial refinement can thus improve the quality of the electron density maps. The researchers find that adding water molecules and including these in the refinement is the single most important step. Adding bound hydrogen atoms to the protein model is also helpful: even though each hydrogen only contributes one electron to the overall density, there are more than enough to make a meaningful difference. Finally, for very high resolution structures (better than 1.5 Å), it can help to treat each atom of the protein individually (anisotropic refinement of B factors, or atomic displacement parameters). However, at lower resolution, doing this can lead to overfitting. Incorporating these steps into the automated process revealed that 25% of fragments would have been missed had conventional methods been used.

The paper includes lots more detail that will be of interest primarily to crystallographers. Moreover, the data for all 364 fragment soaks has been uploaded to the protein data bank. This is a very high-quality data set: all the crystals diffracted to better than 2.0 Å resolution, with the mean being 1.35 Å, and should be a useful resource for those of you establishing your own automated processing system.

03 October 2016

Poll results: affiliation, metrics, and fragment-finding methods

The latest poll has just closed, and the results are quite interesting – I’ll get to these in the next paragraph. First, a quick note on methodology. The poll ran from August 27 through September 30. Due to issues with polling in Blogger, we began running polls in Polldaddy in 2013; its interface gives the total number of votes for a question but not the number of individual respondents. Thus, for the questions on metrics and methods, I assumed that the number of respondents was equal to the number of people who identified themselves as practicing FBLD in the first question, or 123 out of a total of 154. The true percentages for the metrics and methods that people use could be higher or lower if not everyone answered all the questions.

Readership demographics have been remarkably stable since 2010 and 2013, with just over half of respondents from industry, and around 80% of all respondents actively practicing FBLD.


The next question asked about screening methods, and here things get more interesting.

The first thing to notice is that, as we also saw in 2013, nearly all fragment-finding techniques are being used more, with the average user employing 4.1 distinct methods today compared with 3.6 in 2013 and 2.4 in 2011. Ligand-detected NMR has jumped to first place in terms of popularity, with SPR and X-ray crystallography tied for second, followed closely by thermal shift. MST, while still in the minority, has had the largest percentage increase. The use of crystallography has certainly jumped since 2011, which fits with recent publications.

Finally, with regards to metrics, ligand efficiency (LE) continues to dominate, followed by LLE (or LipE), though overall usage of both is down compared with 2014. Only one of the other metrics broke the 10% mark. 
Again, if some practitioners answered the first question of the poll, but not the next two, the use of all methods and metrics could be underestimated. Still, these results seem to fit with what I’ve heard talking with folks – any surprises?